NOTV INOTIV INC

Inotiv Selected as a Winner of the 2023 Top Workplaces USA Award

Inotiv Selected as a Winner of the 2023 Top Workplaces USA Award

WEST LAFAYETTE, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by , a purpose-driven organization that develops solutions to build and brand Top Workplaces. The Top Workplaces program has a 15-year history of surveying more than 20 million employees and recognizing the top organizations across 60 markets for regional Top Workplaces awards.

"The foundation of our success at Inotiv is fostering a culture of connection around our shared purpose of helping our clients bring life-saving therapies to people around the world," said Robert Leasure, Jr., President and CEO of Inotiv. "Over the last four years, as we’ve focused on building a comprehensive suite of services and products, we’ve continued to strive to make Inotiv the first choice for candidates seeking an impactful and fulfilling career in the life sciences industry. We are so pleased for this recognition reflecting such positive sentiment from our Inotiv community. It further strengthens our commitment to ensure that every member of our team feels valued, respected and empowered to grow, innovate and provide exceptional service to our clients,” Mr. Leasure concluded.

Top Workplaces USA celebrates organizations with 150 or more employees that have built great cultures. Over 42,000 organizations were invited to participate in the Top Workplaces USA survey. Winners of the Top Workplaces USA list are chosen based solely on gathered through an employee engagement survey, issued by Energage.

Results are calculated by comparing the survey’s research-based statements, including 15 Culture Drivers that are proven to predict high performance against industry benchmarks.

“Earning a Top Workplaces award is a badge of honor for companies, especially because it comes authentically from their employees,” said Eric Rubino, Energage CEO. “That's something to be proud of. In today's market, leaders must ensure they’re allowing employees to have a voice and be heard. That's paramount. Top Workplaces do this, and it pays dividends.”

About Inotiv

is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: .

About Energage

Making the world a better place to work together.TM

Energage is a purpose-driven company that helps organizations turn employee feedback into useful business intelligence and credible employer recognition through Top Workplaces. Built on 16 years of culture research and the results from 27 million employees surveyed across more than 70,000 organizations, Energage delivers the most accurate competitive benchmark available. With access to a unique combination of patented analytic tools and expert guidance, Energage customers lead the competition with an engaged workforce and an opportunity to gain recognition for their people-first approach to culture. For more information or to nominate your organization, visit or

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental regulations, inspections and investigations, the impact of site closures and consolidations, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.

Company ContactInvestor Relations
Inotiv, Inc.The Equity Group Inc.
Beth A. Taylor, Chief Financial OfficerDevin Sullivan
(765) 497-8381(212) 836-9608



EN
01/02/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INOTIV INC

 PRESS RELEASE

Inotiv Provides Notice Regarding Cybersecurity Incident

Inotiv Provides Notice Regarding Cybersecurity Incident WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. As previously described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on and ...

 PRESS RELEASE

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Pro...

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update –   First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million –   First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million –   Conference call scheduled for today at 8:30 am ET  WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research ...

 PRESS RELEASE

Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and...

Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026 WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Co...

 PRESS RELEASE

Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Ap...

Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced a strategic initiative to leverage LifeNet Health’s proprietary TruVivo® within its Discovery and Translational Sciences business. LifeNet Health, a global leader...

 PRESS RELEASE

Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bi...

Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company providing advanced artificial intelligence (AI) and machine learning (ML) solutions for biomedical research, today announced a strategic collaboration d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch